Automated Manufacturing of Potent CD20-directed CAR T Cells for Clinical Use

Human Gene Therapy - United States
doi 10.1089/hum.2017.111
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

Clinical Trials of Dual-Target CAR T Cells, Donor-Derived CAR T Cells, and Universal CAR T Cells for Acute Lymphoid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Challenges of Driving CD30-directed CAR-T Cells to the Clinic

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Anti-Car-Engineered T Cells for Epitope-Based Elimination of Autologous CAR T Cells

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2019English

GMP-Compliant Manufacturing of NKG2D CAR Memory T Cells Using CliniMACS Prodigy

Frontiers in Immunology
AllergyImmunology
2019English

Engineering CAR-T Cells

Biomarker Research
BiochemistryMolecular MedicineClinical Biochemistry
2017English

CAR T Cells for Acute Lymphoblastic Leukemia

American Journal of Hematology
Hematology
2019English

Armed T Cells With CAR for Cancer Immunotherapy

Science China Life Sciences
GeneticsMolecular BiologyEnvironmental ScienceBiochemistryBiological SciencesAgricultural
2016English

Targeting Glioblastoma With CAR T Cells

Cancer Discovery
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy